Sanofi Comprehensive Income 2010-2024 | SNY

Sanofi comprehensive income from 2010 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
  • Sanofi comprehensive income for the quarter ending September 30, 2024 was $M, a NAN% increase year-over-year.
  • Sanofi comprehensive income for 2023 was $-0.067B, a 104.39% decline from 2022.
  • Sanofi comprehensive income for 2022 was $1.529B, a 250.78% decline from 2021.
  • Sanofi comprehensive income for 2021 was $-1.014B, a 73.57% decline from 2020.
Sanofi Annual Comprehensive Income
(Millions of US $)
2023 $-67
2022 $1,529
2021 $-1,014
2020 $-3,836
2019 $722
2018 $-198
2017 $-661
2016 $2,173
2015 $1,013
2014 $-1,299
2013 $-1,279
2012 $-220
2011 $
2010 $
2009 $
Sanofi Quarterly Comprehensive Income
(Millions of US $)
2024-09-30
2024-06-30 $1,074
2024-03-31
2023-12-31 $-67
2023-09-30
2023-06-30 $437
2023-03-31
2022-12-31 $1,529
2022-09-30
2022-06-30
2022-03-31
2021-09-30
2021-03-31
2020-09-30
2020-03-31
2019-09-30
2019-03-31
2018-03-31
2017-12-31 $-661
2017-09-30
2017-06-30 $228
2017-03-31
2016-12-31 $2,173
2016-09-30
2016-06-30 $611
2016-03-31
2015-09-30
2015-06-30 $1,098
2014-06-30 $-4,611
2013-06-30 $240
2012-06-30 $455
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $121.816B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Innoviva (INVA) United States $1.195B 9.94